

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
666 FIFTH AVENUE, 31ST FLOOR
NEW YORK, NEW YORK 10103-3198
WWW.FULBRIGHT.COM

FACSIMILE TRANSMISSION

DATE: March 11, 2003

MATTER NUMBER: 09905230

RECIPIENT(S):	FAX NO.:	PHONE NO.:
Examiner G. Nichol USPTO, Group 1643	703-305-7230	

FAX RECEIVED

MAR 13 2003

GROUP 1600

OFFICIAL

FROM: Norman Hanson

USER ID: N1101030 FLOOR: 24

PHONE: (212) 318-3168

FAX: (212) 318-3400

RE: LUD 5615

NUMBER OF PAGES WITH COVER PAGE: 4

Message:

--

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYED OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU!


IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
AT _____ AS SOON AS POSSIBLE.

VIA FACSIMILE

LUD S (09905230)-NDH

I hereby certify that this correspondence is being facsimile transmitted to
Commissioner of Patents and Trademarks, Washington, D.C. 20231 on March
11, 2003

Fulbright & Jaworski L.L.P.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : JAGER, et al.
 Serial No. : 09/451,739
 Filed : November 30, 1999
 For : ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODING
 CANCER ASSOCIATED ANTIGENS, THE ANTIGENS PER SE,
 AND USES THEREOF
 Group Art Unit : 1643
 Examiner : G. Nichol

March 11, 2003

Hon. Commissioner of Patents
 and Trademarks
 Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the restriction requirement dated February 14, 2003, applicants elect
 Group XIII, with traverse. In connection with the traverse, applicants submit the amendment
 which follows:

IN THE CLAIMS

Cancel claims 1-79 without prejudice.

Add claims 80-97 which follow:

- Claim 80. An isolated nucleic acid molecule, the complementary sequence of which
 hybridizes, under stringent conditions, to one of the nucleotide sequences set forth
 in SEQ ID NO: 4, 8 or 15.
- Claim 81. The isolated nucleic acid molecule of claim 80, comprising the nucleotide sequence
 of SEQ ID NO: 15.
- Claim 82. The isolated nucleic acid molecule of claim 80, comprising the nucleotide sequence
 of SEQ ID NO: 8.

25272605.1